Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia

Summary

A primary hypothesis to be explored here is that, given its pharmacodynamic profile and hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to placebo, be effective when added to risperidone or olanzapine treated group in reducing the severity of resistant symptoms, particularly existing subsyndromal anxiety and depression.

Timeline

Start

2006-03

Primary completion

—

Completion

2007-07

Drugs

Indications